Radioligand therapy, in depth.

• Beyond PSMA: Emerging Radioligand Therapy Targets in Solid Tumors

  A maintained landscape of next-generation radioligand therapy targets beyond PSMA and SSTR2 — DLL3, FAP, GRPR, Nectin-4, CXCR4, STEAP1 and more, with clinical stage and expression profiles.

• Reading Normal-Tissue Expression for Radioligand Dosimetry Risk

  How normal-tissue RNA and protein expression in kidney, liver, marrow and salivary glands maps to dose-limiting organ risk in radioligand therapy — and where it stops being predictive.

• What Makes a Good Radioligand Therapy Target? A 6-Criteria Framework

  The six properties that decide whether a protein can become a radioligand therapy — cell-surface access, normal-tissue safety, tumor specificity, internalization, clinical maturity, and competition.